Skip to contentV
Veracyte, Inc.
V
VCYTVeracyte, Inc. Q3 2024 · 10-Q
Revenue$115.86M$115.86M+28.6% vs Q3 2023 Net Income$15.16M$15.16MN/M vs Q3 2023 EPS Diluted$0.19$0.19N/M vs Q3 2023 Gross Profit$79,010,000+37.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Veracyte, Inc. · CIK 1384101 · Engraved from SEC EDGAR
Operating Cash Flowderived$29,963,000+111.4% Free Cash Flowderived$27,721,000+143.8% Margins · derivedGross margin68.2%+4.2 pt vs Q3 2023
Operating margin10.4%+45.6 pt vs Q3 2023
Net margin13.1%+45.9 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end